Clinical trials: Advanced Solid Tumors (Phase 1)
Bladder Cancer, Urothelial Carcinoma
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
This hypothetical first-in-human study is designed to evaluate the safety, feasibility, and preliminary anti-tumor activity of an allogeneic dual-target Nectin-4/HER2 CAR-NK cell product in adults with relapsed/refractory locally…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- Trial name
- DUET-UC-NK (NCT07492628)
- Testing
- EB-DT-NK-UC101, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Solid Tumor
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and…
- Trial name
- NCT02048709
- Testing
- GDC-0919
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Genentech, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of carbendazim in treating patients who have advanced solid…
- Trial name
- NCT00003709
- Testing
- carbendazim
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Gastric Cancer, Esophageal Cancer
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
Although declining in incidence, gastric/gastroesophageal cancer is still a commonly diagnosed malignancy in Canada. Patients who have undergone surgical resection for early disease have a high rate of local recurrence and…
- Conditions
- Gastric Cancer, Esophageal Cancer, Tumors
- Trial name
- NCT00130936
- Testing
- Epirubicin, Carboplatin, Capecitabine
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- AHS Cancer Control Alberta
Advanced Solid Tumors
Study of CM529D1 in Participants With Advanced Solid Tumors
This is interventional study to evaluate the safety and tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CM529D1 in participants with advanced solid tumors.
- Trial name
- NCT07893171
- Testing
- CM529D1
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Keymed Biosciences Co.Ltd
Myeloid Malignancies, Acute Lymphocytic Leukemia
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute…
- Conditions
- Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphomas, Advanced Solid Tumors
- Trial name
- NCT05775406
- Testing
- KT-253
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- Kymera Therapeutics, Inc.
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore MSC2156119J, in subjects with advanced solid tumors who have not responded to previous therapies or for whom no other therapies are available.
- Trial name
- NCT01014936
- Testing
- MSC2156119J
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- EMD Serono
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
To evaluate the safety and tolerability of Oprozomib in patients with advanced refractory or recurrent solid tumors including determination of its Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) To determine the…
- Trial name
- NCT01129349
- Testing
- Oprozomib
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Amgen
Advanced Solid Tumor
Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor
RATIONAL: Simmitecan is an anticancer ester prodrug, which involves activation to chimmitecan. Chimmitecan，a novel CPT derivative, exhibited potent antitumor activities both in vitro and in vivo by inhibiting topoisomerase I.
- Trial name
- NCT01832298
- Testing
- Simmitecan Hydrochloride for Injection
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Advanced Solid Tumor
TT-00973-MS Tablets in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TT-00973-MS tablets in patients with solid tumors.
- Trial name
- NCT05673538
- Testing
- TT-00973-MS tablets treatment
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumors
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
This study is for people with advanced cancer for which no curative treatment exists. The purpose of this study is to test the safety and effectiveness of the combination of the drugs Temsirolimus and Capecitabine and see what…
- Trial name
- NCT01050985
- Testing
- Temsirolimus and capecitabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Georgetown University
Advanced Solid Tumors
HV-101 for Patients With Advanced Solid Tumors
Background: Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy by harvesting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro and then infusing back to treat patients.
- Trial name
- NCT05868915
- Testing
- HV-101
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Hervor Therapeutics
Solid Tumor
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）
This is a Phase I study designed to evaluate if LB4330, an anti-Claudin 18.2 and CD8 T cell activator fusion protein, is safe, tolerable and efficacious in participants with Advanced Solid Tumors
- Trial name
- MEETCD8-001 (NCT05707676)
- Testing
- LB4330
- Where
- China
- Volunteers
- 40 people
- Sponsor
- L & L Bio Co., Ltd., Ningbo, China
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of PI3Kbeta inhibitor AZD8186 when given together with docetaxel in treating patients with solid tumors with PTEN or PIK3CB mutations that have spread to other places in…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03218826
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Solid Tumors
Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors
VELCADE has demonstrated marked activity in haematological cancers leading to registration (MM, MCL). Currently only biweekly or weekly regimens have been explored.
- Trial name
- VELDAY (NCT02220049)
- Testing
- Bortezomib
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Adult Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
This phase I clinical trial studies the side effects and the best dose of azacitidine and oxaliplatin in treating patients with advanced cancers that do not respond to treatment or have returned after any platinum therapy.
- Trial name
- NCT01039155
- Testing
- Azacitidine, Laboratory Biomarker Analysis, Oxaliplatin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor Malignancy
Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients
Stage 1 (Safety study for 68Ga-NRT6020 Injection): The goal of this clinical trial stage is to evaluate the safety of 68Ga-NRT6020 Injection in participants with advanced solid tumors.
- Trial name
- NCT06911489
- Testing
- 68Ga-NRT6020 Injection, 177Lu-NRT6020 Injection (stage 2), 177Lu-NRT6020 Injection (stage 3)
- Where
- 2 sites in China
- Volunteers
- 132 people
- Sponsor
- Chengdu New Radiomedicine Technology Co. LTD.
Advanced Solid Tumors
A Phase I Study of JS108 in Patients With Advanced Solid Tumors
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS108 for patients with advanced solid tumors.
- Trial name
- NCT04601285
- Testing
- JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Sarcoma, Lung Cancers
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
- Conditions
- Sarcoma, Lung Cancers, Melanoma
- Trial name
- NCT06942143
- Testing
- Super1 TCR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.